Capitalist Science

The economic structure of basic science is currently socialist, funded by the public at large through taxes for the benefit of the public at large. This socialist system should be augmented by a capitalist system, in which basic science is also funded by private investors who reap financial benefit from the sale of subsequent technologies based on the knowledge obtained from the research funded by their investments. A capitalist system will provide benefits extending from the broad target audience of this paper – which includes politicians, financiers, economists, and scientists in all fields – to the average taxpayer and consumer. Capitalist science will better align the incentives of scientists with taxpayer interests, channel more money into basic science, lower your taxes, and generally improve the quality of your life.

💡 Research Summary

The paper “Capitalist Science” argues that the current funding model for basic research—largely a publicly financed, “socialist” system—suffers from a classic tragedy of the commons. Because scientific knowledge is non‑rival and freely available, individual investors lack a direct financial incentive to fund long‑term, high‑risk basic research. Consequently, scientists are rewarded primarily through short‑term metrics such as publication counts and citations, which do not necessarily align with the broader societal benefits that basic science can generate (e.g., climate‑change solutions).

To remedy this misalignment, the author proposes a “capitalist science” framework that augments public funding with private investment. The central mechanism is a modest future tax (illustrated as 1 % of corporate revenue) that would be levied on companies ten years from now. The revenue from this tax would be redistributed directly—not through discretionary government spending—to the individuals and entities that have previously funded basic research. Distribution would be based on a quantitative assessment of each researcher’s contribution to the “belief update” of scientific hypotheses, using a Bayesian‑style belief‑tracking database.

In practice, researchers would no longer publish solely in traditional journals. Instead, they would submit entries to a publicly accessible database that specify the hypothesis tested, the prior belief, and the posterior belief after the experiment. Companies that rely on certain hypotheses for their products would query this database, identify the researchers whose work most increased the confidence in those hypotheses, and automatically allocate a share of the future tax revenue to them. Private investors would finance research enterprises (some of which could become publicly traded) and receive risk‑adjusted returns when the associated companies later pay the tax. A secondary market would allow investors to sell their stakes before all future cash flows are realized, providing liquidity.

The proposal claims several benefits: (1) it aligns scientists’ incentives with the interests of taxpayers and end‑users; (2) it channels additional capital into basic research without raising current tax burdens, because the tax is a redistribution of existing government spending; (3) it creates a real‑time market for scientific belief updates, encouraging more rigorous quantification of research outcomes; and (4) it reduces the reliance on government appropriations over time as private capital takes on a larger share of basic‑science funding.

The paper also anticipates criticisms. It argues that openness will not be harmed—in fact, monetary rewards for useful results should increase data sharing. It maintains that taxes are not increased; the proposed levy merely redirects money that would otherwise be at the government’s discretion. Potential downsides such as concentration of capital in fashionable fields, the administrative complexity of maintaining a belief‑tracking database, and the risk of “gaming” the system are acknowledged, with a brief suggestion that regulatory oversight and insurance mechanisms would be needed.

In summary, “Capitalist Science” offers a hybrid funding model that blends a future corporate revenue tax with a market‑based reward system for basic research contributions. By doing so, it seeks to correct the incentive failures of the current public‑only system, attract private capital, and ultimately accelerate scientific progress and its downstream benefits to society.